Hi sankaido
Yes i do remember and thank you for your kind words, they are very much appreciated
With regards to the Capricor DMD Advisory Board situation i wouldn't read to much into it i think this should basically explain it
Capricor Announces Formation Of Duchenne Muscular Dystrophy Advisory BoardPublished: May 25, 2017
LOS ANGELES, May 25, 2017 /PRNewswire/ --
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that, in connection with its growing commitment to the development of CAP-1002 for Duchenne muscular dystrophy (DMD), it has formalized an advisory board composed of key opinion leaders in the field.
Capricor's DMD Advisory Board includes the following members:
| Column 1 | Column 2 |
|---|
| 1 | Barry Byrne, M.D., Ph.D. | University of Florida (USA) |
|---|
| 2 | Michelle Eagle, Ph.D., M.Sc., MCSP | Atom International Ltd (UK) |
|---|
| 3 | Richard Finkel, M.D. | Nemours Children's Hospital (USA) |
|---|
| 4 | Pat Furlong | Parent Project Muscular Dystrophy (USA) |
|---|
| 5 | Kan Hor, M.D. | Nationwide Children's Hospital (USA) |
|---|
| 6 | John Jefferies, M.D. | Cincinnati Children's Hospital Medical Center (USA) |
|---|
| 7 | Oscar Henry Mayer, M.D. | Children's Hospital of Philadelphia (USA) |
|---|
| 8 | Eugenio Mercuri, M.D., Ph.D. | Catholic University of the Sacred Heart (Italy) |
|---|
| 9 | Francesco Muntoni, M.D. | University College London (UK) |
|---|
| 10 | Ron Victor, M.D. | Cedars-Sinai Medical Center (USA) |
|---|
| 11 | Thomas Voit, M.D. | University College London (UK) |
|---|
Linda Marbán, Ph.D., president and CEO of Capricor, said, "We are gratified to have the attention and support of some of the foremost thought leaders in Duchenne muscular dystrophy, several of whom we have been working with since last fall. Following our recent announcement of positive clinical data in DMD with CAP-1002, we have formalized these relationships by assembling what we believe is a world-class advisory board of Duchenne specialists."
"With their collaboration, we are planning the next steps in CAP-1002's development in DMD, including the design of a randomized, double-blind, placebo-controlled clinical trial of intravenous, repeat-dose CAP-1002 in which we expect to begin patient enrollment in the latter half of this year, subject to regulatory approval," added Dr. Marbán
I would imagine they get a retainer of sorts for their registered association with capricor and a fee when called upon, i would say it is more of a professional way of backing themselves in, in a marketing way by showing they are in touch with leaders in the field within which they are targeting, that being DMD
Its no more than we do, we just have to lift our game in the marketing space thats all
Did you note that magic word i followed up with Sankaido its slapped in their description
KOL Key opinion leaders in their field
I dare say if we could put
Pat furlong PPMDand the following KOl
Dr Ian Woodcock, Paediatric Neurologist and Honorary Fellow at The Murdoch Children’s Research Institute, Melbourne and the Principal Investigator of the ATL1102 Phase II DMD trial said, “the study met its primary endpoint showing ATL1102 to be safe and well tolerated with no serious adverse events being reported and no participant withdrawing from the study. With very few treatment options for boys with Duchennes who are no longer ambulant, it has been great to enable the boys to participate in this clinical trial and I am most encouraged by the outcomes of the study”
Dr Jean-Yves Hogrel, PhD, Director of the Neuromuscular Physiology and Evaluation Laboratory, Institute of Myology, France, a developer of the MyoSet assessment tools stated that “First, I would like to highlight the quality of the data that proves the expertise and dedication of evaluators in following standardised operating procedures. The intra-individual variability is very moderate and reflects this measurement quality. My observations based on the MyoSet data from the study suggest that the patients were generally stable.”
Dr Hogrel stated that “this positive correlation of remaining muscle area (the lean muscle), with grip strength suggests a consistency of the results across the different parameters of muscle structure and muscle force.”
Professor Thomas Voit MD, Director, NIHR GOSH Biomedical Research Centre, UK had this to say about the trial results and the efficacy being observed in this Phase II trial of ATL1102: “The data certainly suggests an overall ‘stabilisation’ in disease progression at the very least which of itself is a very positive clinical outcome. MRI data confirms the positive changes at a muscular/cellular level and supports the observed physical stabilisation/improvements in muscle strength and function. The consistency of positive clinically relevant effects of ATL1102 treatment across muscle measures of structure, strength and function are very pleasing and provide great encouragement for the treatment of non-ambulant patients with DMD”
Dr Gil Price M.D., ANP’s Consultant Medical Director, said: “In a small study with nine boys of only six months duration at a single low dose we not only achieved our primary endpoint of safety we also i) achieved significance in demonstrating an effect on our secondary endpoint relating to modulation of CD49d; ii) achieved positive outcomes in the important upper body function parameter of the PUL 2.0 test, and finally iii) achieved fat fraction percentage reduction in important upper body muscles. That each of these three effects were observed in an initial study in DMD boys at the lowest dose where we might have anticipated a biological effect is truly surprising and highly encouraging”
Plus there are more we could add
These are all people we have consulted even though they may well be attached to other companies,
I suppose what Capricor have done, is engage a number of leaders in the DMD field with whom they engage if needed and called them collectively a formalized board, so in effect they are not really board members
of Capricor but more a board of
advisors for capricor, and yes i would assume as i mentioned there would be a fee but this does not give capricor exclusivity or access to privileged information that those advisors may hold from within other companies they chose or have chosen to engage with.
To be quite honest sankaido Even With Prof Voit as PI i dont see a problem Capricor and ANP are two totally different drugs in play. We have 1102 patented up to the eyeballs totally different mechanisms
The trial is going to be placebo based so no real results are going to come out until trial completion anyway
Why would you be surprised to have Pat Furlong involved with Capricor as a named Kol she is at the top of her game and has lost two children to the disease, no one knows this illness better than her in my opinion hence why she is classed in this league of experts.
If we are to head towards the Nasdaq as i have mentioned then yes from a professional point of view it would pay ANP from a investment marketing point of view to do something similar and configure our own muscular Disease Board covering all aspects of the disease what with other indications coming forwards, This is where ANP have to grow up as a company, in both the marketing and appearance department from an investment point.
Capricor are the least of my worries at this moment in time
My major concern ( worry ) is this next financial company making move
Some folks say dont care if its a CR well if it is a CR we are in for a lot longer ride to where we want to get to, as opposed to doing a deal to the magnitude that i have covered
Hope this Helps sankaido
Gl to us and thank you once more for your kind words
See how we go
(20min delay)
